{"id":4490,"date":"2025-09-16T12:21:35","date_gmt":"2025-09-16T09:21:35","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4490"},"modified":"2025-09-16T12:31:54","modified_gmt":"2025-09-16T09:31:54","slug":"givinostat-duvyzat-distribution-brazil","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/givinostat-duvyzat-distribution-brazil\/","title":{"rendered":"Italfarmaco und Multicare Pharma unterzeichnen exklusiven Vertriebsvertrag f\u00fcr Givinostat (Duvyzat), ein DMD-Medikament in Brasilien"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Italfarmaco gab eine Exklusivvereinbarung mit Multicare Pharma bekannt, einem f\u00fchrenden Pharmaunternehmen in Lateinamerika. <strong>Multicare Pharma wird die beh\u00f6rdliche Zulassung in Brasilien unterst\u00fctzen und Givinostat (Duvyzat) vertreiben, Italfarmacos neuartigen Histon-Deacetylase-Hemmer (HDAC) zur Behandlung der Duchenne-Muskeldystrophie (DMD).<\/strong> Gem\u00e4\u00df den Vertragsbedingungen \u00fcbernimmt Multicare die Versorgung und den Vertrieb des Medikaments in Brasilien. Finanzielle Details wurden nicht bekannt gegeben. \u2013 Lesen Sie: <a href=\"https:\/\/dmdwarrior.com\/de\/duvyzat-givinostat-nonsteroidal-drug\/\" data-type=\"post\" data-id=\"3957\">Was ist Duvyzat?<\/a> \u2013<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201eBei Italfarmaco pr\u00e4gt unser Engagement f\u00fcr seltene Krankheiten jede unserer Entscheidungen. Der Zugang zu Givinostat kann f\u00fcr Patienten mit DMD in Brasilien einen bedeutenden Unterschied machen\u201c, sagte Antonio Nardi, Vizepr\u00e4sident und Leiter der Gesch\u00e4fts- und Portfolioentwicklung von Italfarmaco. \u201eDie Partnerschaft mit Multicare, einem f\u00fchrenden Unternehmen auf dem Gebiet seltener und hochkomplexer Krankheiten mit gro\u00dfer Reichweite in ganz Brasilien, erm\u00f6glicht es uns, diese innovative Behandlung denjenigen zug\u00e4nglich zu machen, die sie am dringendsten ben\u00f6tigen.\u201c<\/p>","protected":false},"excerpt":{"rendered":"<p>Italfarmaco announced an exclusive agreement with Multicare Pharma, a prominent pharmaceutical company in Latin America. Multicare Pharma will support the regulatory approval in Brazil and distribute givinostat (Duvyzat), Italfarmaco\u2019s novel histone deacetylase (HDAC) inhibitor to treat Duchenne muscular dystrophy (DMD). According to the terms of the agreement, Multicare will manage supply and distribution operations for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4491,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[82,46,47,311,420],"class_list":["post-4490","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-brazil","tag-duvyzat","tag-givinostat","tag-italfarmaco","tag-multicare-pharma"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=4490"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/4491"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=4490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=4490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=4490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}